Lithium in children shows a renal, thyroid and gut reporting pattern, and a broad safety screen of PCSK9 inhibitors turns up little

The edition in brief

A disproportionality analysis of spontaneous reports in the WHO VigiBase database compared lithium (29,897 reported adverse reactions) with second-generation antipsychotics across age groups. In children, lithium had a higher proportion of renal, endocrine, gastrointestinal, skin and cardiac reports than the antipsychotics, thyroid reactions were proportionally more common in children, and serious renal outcomes were proportionally more common in older adults. This design cannot give incidence or prove causation. A signal-detection study combining French national health data (36,163 PCSK9 inhibitor initiators against 34,269 ezetimibe initiators, 700 outcomes) and VigiBase found two potential signals, for inhaled glucocorticoid and colony-stimulating factor initiations, both judged likely to reflect confounding or indication bias. A physiologically based pharmacokinetic model of tedizolid proposed regimens for children aged 2 to 18 that reached the target exposure at an MIC of 0.5 mg/L; it is a simulation, not a trial. A review of generic brand switching examines why switches may be followed by reports of adverse effects or failure. The FDA database records a supplement for atezolizumab (Tecentriq) with no detail. The pearl covers reporting suspected adverse reactions in India.